The Pro12Ala polymorphism of peroxisome proliferator-activated receptor-γ2 gene is associated with plasma levels of soluble RAGE (Receptor for Advanced Glycation Endproducts) and the presence of peripheral arterial disease

Clinical Biochemistry

Volumn 41, Issue 12, 2008, Pages 981-985

  Catalano, Mariella ^a   Cortelazzo, Adriano ^a   Santi, Roberto ^b   Contino, Laura ^b   Demicheli, Marta ^b   Yilmaz, Yusuf ^c   Zorzetto, Michele ^d   Campo, Ilaria ^d   Lanati, Niccolò ^e   Emanuele, Enzo ^e  

^a UNIVERSITY OF MILAN   (Italy)

^b SS Antonio e Biagio   (Italy)

^c ULUDAG UNIVERSITY   (Turkey)

^d FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^e UNIVERSITY OF PAVIA   (Italy)

Author keywords

Genetics; Peripheral arterial disease; Peroxisome proliferator activated receptor; Polymorphism; Receptor for advanced glycation end products

Indexed keywords

ADVANCED GLYCATION END PRODUCT RECEPTOR; ALANINE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA 2; PROLINE;

ADULT; AGED; ALLELE; ARTERY DISEASE; ARTICLE; CARDIOVASCULAR RISK; CONFIDENCE INTERVAL; CONFOUNDING VARIABLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC RISK; GENOTYPE; HUMAN; ITALY; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; POLYMERASE CHAIN REACTION; PREVALENCE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM;

AGED; ALANINE; ALLELES; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; CONFIDENCE INTERVALS; DNA; FEMALE; GENOTYPE; HUMANS; ITALY; LOGISTIC MODELS; MALE; MIDDLE AGED; ODDS RATIO; PERIPHERAL VASCULAR DISEASES; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; PPAR GAMMA; PROLINE; RECEPTORS, IMMUNOLOGIC; RISK FACTORS;

EID: 47049130311     PISSN: 00099120     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2008.05.007     Document Type: Article

References (18)

1. Shammas N.W. Epidemiology, classification, and modifiable risk factors of peripheral arterial disease. Vasc Health Risk Manag 3 (2007) 229-234
2. Signorelli S.S., Mazzarino M.C., Spandidos D.A., and Malaponte G. Proinflammatory circulating molecules in peripheral arterial disease. Int J Mol Med 20 (2007) 279-286
3. Li J., and Wang N. Peroxisome proliferator-activated receptor-gamma in vascular biology. Cardiovasc Hematol Disord Drug Targets 7 (2007) 109-117
4. Ziouzenkova O., Perrey S., Marx N., Bacqueville D., and Plutzky J. Peroxisome proliferator-activated receptors. Curr Atheroscler Rep 4 (2002) 59-64
5. Matsui T., Yamagishi S., Ueda S., et al. Telmisartan, an angiotensin II type 1 receptor blocker, inhibits advanced glycation end-product (AGE)-induced monocyte chemoattractant protein-1 expression in mesangial cells through downregulation of receptor for AGEs via peroxisome proliferator-activated receptor-gamma activation. J Int Med Res 35 (2007) 482-489
6. Yoshida T., Yamagishi S., Nakamura K., et al. Telmisartan inhibits AGE-induced C-reactive protein production through downregulation of the receptor for AGE via peroxisome proliferator-activated receptor-gamma activation. Diabetologia 49 (2006) 3094-3099
7. Koyama H., Yamamoto H., and Nishizawa Y. RAGE and soluble RAGE: potential therapeutic targets for cardiovascular diseases. Mol Med 13 (2007) 625-635
8. Basta G. Receptor for advanced glycation endproducts and atherosclerosis: from basic mechanisms to clinical implications. Atherosclerosis 196 (2008) 9-21
9. Geroldi D., Falcone C., and Emanuele E. Soluble receptor for advanced glycation end products: from disease marker to potential therapeutic target. Curr Med Chem 13 (2006) 1971-1978
10. Doney A.S., Fischer B., Leese G., Morris A.D., and Palmer C.N. Cardiovascular risk in type 2 diabetes is associated with variation at the PPARG locus: a Go-DARTS study. Arterioscler Thromb Vasc Biol 24 (2004) 2403-2407
11. Li L., Cheng L.X., Nsenga R., He M.A., and Wu T.C. Association between Pro12Ala polymorphism of peroxisome proliferator-activated receptor-gamma 2 and myocardial infarction in the Chinese Han population. Clin Cardiol 29 (2006) 300-304
12. Ruiz-Narváez E.A., Kraft P., and Campos H. Ala12 variant of the peroxisome proliferator-activated receptor-gamma gene (PPARG) is associated with higher polyunsaturated fat in adipose tissue and attenuates the protective effect of polyunsaturated fat intake on the risk of myocardial infarction. Am J Clin Nutr 86 (2007) 1238-1242
13. Deeb S.S., Fajas L., Nemoto M., et al. A Pro12Ala substitution in PPARgamma2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity. Nat Genet 20 (1998) 284-287
14. Ek J., Urhammer S.A., Sørensen T.I., et al. Homozygosity of the Pro12Ala variant of the peroxisome proliferation-activated receptor-gamma2 (PPAR-gamma2): divergent modulating effects on body mass index in obese and lean Caucasian men. Diabetologia 42 (1999) 892-895
15. Yan S.F., Naka Y., Hudson B.I., et al. The ligand/RAGE axis: lighting the fuse and igniting vascular stress. Curr Atheroscler Rep 8 (2006) 232-239
16. Falcone C., Emanuele E., D'Angelo A., et al. Plasma levels of soluble receptor for advanced glycation end products and coronary artery disease in nondiabetic men. Arterioscler Thromb Vasc Biol 25 (2005) 1032-1037
17. Franks P.W., Jablonski K.A., Delahanty L., et al. The Pro12Ala variant at the peroxisome proliferator-activated receptor gamma gene and change in obesity-related traits in the Diabetes Prevention Program. Diabetologia 50 (2007) 2451-2460
18. Nawroth P.P., and Stern D.M. Soluble forms of RAGE: an index of vascular stress? A commentary on "Soluble RAGE in type 2 diabetes: association with oxidative stress". Free Radic Biol Med 43 (2007) 506-510